Clinician’s Perspectives on the use of Vildagliptin and its Fixed-Dose Combination with Metformin in the Management of Type 2 Diabetes Mellitus in India
Advances in Diabetes & Endocrinology · 2025
DOI: 10.13188/2475-5591.1000020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Diabetes & Endocrinology, 2025. Verfasst von S Manjula.
Themen: Diabetes mellitus
Abstract (Originalsprache)
in the initiation and management of pharmacotherapy for T2DM, with a particular focus on the role of vildagliptin and its fixed-dose combination (FDC) with metformin.
Zitieren
APA
Manjula, S. (2025). Clinician’s Perspectives on the use of Vildagliptin and its Fixed-Dose Combination with Metformin in the Management of Type 2 Diabetes Mellitus in India. Advances in Diabetes & Endocrinology. https://doi.org/10.13188/2475-5591.1000020
Vancouver
Manjula S. Clinician’s Perspectives on the use of Vildagliptin and its Fixed-Dose Combination with Metformin in the Management of Type 2 Diabetes Mellitus in India. Advances in Diabetes & Endocrinology. 2025. doi:10.13188/2475-5591.1000020
BibTeX
@article{Manjula2025,
author = {Manjula, S},
title = {Clinician’s Perspectives on the use of Vildagliptin and its Fixed-Dose Combination with Metformin in the Management of Type 2 Diabetes Mellitus in India},
journal = {Advances in Diabetes & Endocrinology},
year = {2025},
doi = {10.13188/2475-5591.1000020}
}
EUVIMED